A

Alnylam Pharmaceuticals

Develops RNAi-based therapies for genetic diseases

Associate Director CMC Team Lead

Bioprocess & BiomanufacturingConfirmed live in the last 24 hours
Full-timeCambridge, MA, USA$161.5k - $218.5k

About the Job

Requirements

  • An advanced degree in life sciences, pharmaceutical sciences, chemical engineering, bioengineering, or a related field.
  • Technical knowledge of new modalities and ability to have seamless conversations with internal and external stakeholders.
  • Relevant industry experience in CMC, pharmaceutical development, technical operations, program leadership, or external development.
  • Proven experience acting as CMC team lead for biologics or complex/hybrid modalities.
  • Experience working on cross-functional drug development teams.
  • Experience managing complex timelines, dependencies, and external partners such as CDMOs.
  • Strong understanding of early-phase CMC development and modality-related development risk.
  • Ability to evaluate CDMOs for early-phase work and onboard partners rapidly.
  • Experience working with emerging modalities such as Antibody Oligo Conjugates (AOCs), Peptide Oligo Conjugates (POCs), peptides, biologics, or related platforms.
  • Ability to translate technical complexity into clear plans, risks, and decisions for leadership.

Responsibilities

  • Lead downstream process development strategy for emerging modalities, emphasizing antibody purification and Antibody Oligo Conjugation purification.
  • Design and oversee phase-appropriate purification processes that are scalable, robust, and aligned with early clinical development needs.
  • Establish purification approaches for novel and non-platform molecules, including capture and polishing strategy, ultrafiltration/diafiltration, impurity clearance, yield optimization, and process robustness.
  • Partner with the internal conjugation team to align downstream purification processes and control strategies with conjugated product attributes and program development needs.
  • Work with Analytical Development to define control strategies, characterize process performance, and link process design with product quality.
  • Address purification challenges for complex and conjugated molecules, including removal of residual species, aggregates, unconjugated components, process-related impurities, and modality-specific quality risks.
  • Provide technical leadership for downstream activities at CDMOs, including process design, study oversight, data review, troubleshooting, process transfer, and support of GMP manufacturing campaigns.
  • Collaborate with antibody development, formulation, analytical, regulatory, and operations teams to ensure an integrated, phase-appropriate CMC strategy through Phase I.
  • Author and review downstream sections of technical reports and regulatory submission documents, including support for IND and other early clinical CMC filings.
  • Serve as the downstream technical subject matter expert in regulatory-facing discussions on purification process design, control strategy, process characterization, comparability considerations, and manufacturing readiness.
  • Identify technical risks, development gaps, and scalability concerns early, and provide recommendations to support program progression and handoff into later-stage development.
  • Build and standardize downstream development practices, technical frameworks, and lessons learned to improve repeatability across antibody- and conjugate-based modalities.
  • Lead CMC programs and guide development from preclinical stages toward human proof of concept and Phase I execution.
  • Build and manage integrated development plans, support development readiness packages, and help shape external partner and CDMO strategy for early-phase programs.
  • Establish credible, phase-appropriate paths into early development and Phase I execution, reducing late-stage CMC surprises and strengthening planning for emerging modalities.

About the Company

Alnylam Pharmaceuticals

Develops RNAi-based therapies for genetic diseases

Alnylam Pharmaceuticals develops RNA interference (RNAi) therapeutics to silence disease-causing genes, aiming to treat rare genetic disorders. Its products work by using RNA molecules that block gene expression, reducing the impact of specific genetic diseases. The company differentiates itself by concentrating on RNAi-based drugs for rare diseases and by building a pipeline through large clinical programs and strategic partnerships, such as commercialization deals in the Gulf States and collaborations with investors. Revenue comes from approved drug sales, licensing agreements, strategic collaborations, and related services like genetic testing and counseling. The company’s goal is to advance and commercialize RNAi therapies to improve outcomes for patients with genetic disorders, expanding its portfolio through partnerships and investments.

Company size
1,001-5,000
Company stage
IPO
Headquarters
Cambridge, MA
Founded
2002

Recently Posted Jobs

Explore more opportunities at Alnylam Pharmaceuticals

See more jobs